A new study has demonstrated the potential cancer risk reduction associated with a certain class of antiepileptic drug (AED).
The research, conducted at Kinki University, in Osaka, used a variety of different methods, algorithms and databases to explore whether or not the use of sodium channel-blocking AEDs is linked to a decreased risk of cancer.
Data on more than 65 million ‘drug-reaction pairs’* from the first quarter of 2004 through to the end of 2013 were downloaded from the US Food and Drug Administration’s Adverse Event Reporting System, to identify whether an association between AED usage and cancer existed.
Results from the database analyses, published in the International Journal of Medical Sciences, showed that the use of sodium channel-blocking AEDs was linked to a significantly lower risk of being diagnosed with colorectal, lung and gastric cancer, and  haematological malignancies.
Also importantly, no association was found between the use of this type of AED and an increased risk of any particular type of cancer.
The researchers concluded: “Multi-methodological approaches using different methodologies, algorithms and databases suggest that sodium channel-blocking AED use is inversely associated with colorectal cancer, lung cancer, gastric cancer and haematological malignancies.”
*Where records show that a particular reaction has been reported by someone taking a specific drug, i.e. the drug has been associated with, or ‘paired’ with, that reaction.
Posted by Steve Long
Edited by Epilepsy Research UK
Click here for more articles about anti-epileptic drugs and pregnancy risks.